Index Entries

José Morgenstern, José N Redondo, Albida De León, Juan Manuel Canela, Nelson Torres Castro, Johnny Tavares, Miguelina Minaya, Óscar López, Ana Castillo, Ana María Plácido, Rafael Peña Cruz, Yudelka Merette, Marlenin Toribio, Juan Asmir Francisco, and Santiago Roca
February 2, 2021
Journal of Clinical Trials
Centro Médico Punta Cana (Dominican Republic)

Abstract: … In the present Retrospective observational study, 3,099 patients with a definitive or highly probable diagnosis of infection due to COVID-19 were evaluated… A total of 2,706 (87.3%) were discharged for outpatient treatment, all with mild severity of the infection… In 2,688 (99.33%) with outpatient treatment, the disease did not progress to warrant further hospitalization and there were no deaths. In 16 (0.59%) with outpatient treatment, it was necessary their subsequent hospitalization to a room without any death. In 2 (0.08%) with outpatient treatment, it was necessary their admission to the Intensive Care Unit (ICU) and 1 (0.04%) patient died. There were 411 (13.3%) patients hospitalized, being admitted at a COVID-19 room with a moderate disease 300 (9.7%) patients of which 3 (1%) died; and with a severe to critical disease were hospitalized in the ICU 111 (3.6%), 34 (30.6%) of whom died. The mortality percentage of patients admitted to the ICU of 30.6% is similar with the percentage found in the literature of 30.9%. Total mortality was 37 (1.2%) patients, which is much lower than that reported in world statistics, which are around 3%, by the time of completion of this study.”

document
COVID-19,ivermectin,medical treatments,pharmaceuticals